A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Clinical trial NCT03565445 · COMPLETED
Trial details
- NCT number
- NCT03565445
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-02
- Primary completion
- 2023-03-27
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.